Ipsen obtains development and commercial rights to mesdopetam
Ipsen and IRLAB have signed a licensing agreement, providing Ipsen exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist.
Mesdopetam is...